We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Covaxin was well-tolerated and the Data Safety Monitoring Board has not reported any safety concerns related to the vaccine, the company said in a statement.